United States Patent 4,530,839: Scope, Claims, Expiration, and Contraceptive Patent Landscape

U.S. Patent 4,530,839 protected a triphasic oral contraceptive regimen using a constant estrogen dose, three escalating seven-day progestogen doses, and a seven-day hormone-free interval. Its commercial embodiment corresponds closely to the norethindrone/ethinyl estradiol 0.5 mg/0.75 mg/1.0 mg triphasic regimen historically marketed in products such as Ortho-Novum 7/7/7 and Tri-Norinyl. The patent issued July 23, 1985, and its 17-year pre-URAA term expired July 23, 2002. It no longer creates an enforceable U.S. patent barrier or current generic-entry risk.[1]

What does U.S. Patent 4,530,839 protect?

The patent protects a method of contraception, not a standalone chemical entity or tablet composition. The central regimen requires:

Regimen element	Claimed requirement
Patient	Female of childbearing age
Treatment duration	21 successive days
Estrogen	Constant daily dose throughout all three treatment weeks
Progestogen, days 1-7	Activity corresponding to 0.125-0.75 mg norethindrone
Progestogen, days 8-14	Activity corresponding to 0.50-1.0 mg norethindrone
Progestogen, days 15-21	Activity corresponding to 0.75-2.0 mg norethindrone
Hormone-free interval	Seven days without estrogen or progestogen
Estrogen activity	Corresponding to 0.02-0.05 mg ethinyl estradiol
Administration	Oral administration is claimed in dependent claim 2
Dosage form	Estrogen and progestogen may be administered in admixture

The invention is therefore defined by the sequence and relative dosage pattern. The patent does not broadly cover every oral contraceptive containing ethinyl estradiol and norethindrone. A product must practice the claimed triphasic schedule, or a method of use must be shown to do so, to fall within the core claim scope.

How should claim 1 of U.S. 4,530,839 be construed?

Claim 1 is the broadest independent claim. It has five material limitations.

1. A contraceptive method

The claim requires administration for contraception. A product containing the same hormones but sold or used for another purpose would not necessarily satisfy this limitation.

2. Three successive seven-day treatment phases

The method requires three consecutive seven-day periods. The progestogen activity must increase across the phases:

First week: 0.125-0.75 mg norethindrone-equivalent activity
Second week: 0.50-1.0 mg
Third week: 0.75-2.0 mg

The ranges overlap. For example, a first-week dose of 0.5 mg, second-week dose of 0.75 mg, and third-week dose of 1.0 mg falls within all three claimed ranges.

The claim does not require that the progestogen mass itself increase if the selected progestogens have different biological potencies. It uses norethindrone as the reference for "progestogenic activity." That language expands the claim beyond a formulation containing norethindrone alone, while creating an evidentiary issue over potency equivalence.

3. A constant estrogen dose

The estrogen dose must remain the same during each of the three seven-day periods. Claim 1 allows a daily estrogenic activity corresponding to 0.02-0.05 mg of 17α-ethinylestradiol.

A regimen using 0.035 mg ethinyl estradiol in each active tablet satisfies this limitation. A regimen that changes estrogen dose between weeks would fall outside the literal scope of claim 1, even if its progestogen schedule is identical.

4. A seven-day hormone-free interval

The method must be followed by seven days without estrogen or progestogen administration. A continuous 28-day regimen containing hormones in all 28 tablets would not satisfy the claim as written.

The claim does not expressly require placebo tablets. The hormone-free interval can be implemented with placebo tablets, no tablets, or another administration schedule, provided the claimed method is practiced.

5. A female of childbearing age

This patient limitation narrows the claim to contraceptive use in the specified population. It is consistent with the intended clinical use but can complicate proof in an infringement case if the accused activity is a general product sale rather than actual administration.

What do claims 2 through 9 add?

What does claim 2 cover?

Claim 2 limits claim 1 to oral administration. It captures the conventional oral contraceptive tablet regimen but excludes nonoral delivery systems such as transdermal patches, vaginal rings, implants, or injections unless the administration is also oral.

What does claim 3 cover?

Claim 3 requires the estrogen and progestogen to be administered in admixture. A combined tablet containing both hormones is the principal commercial embodiment. Separate administration of the estrogen and progestogen would not literally satisfy this dependent claim, although it could remain within claim 1.

What does claim 4 cover?

Claim 4 identifies four progestogens:

d-Norgestrel
Norethindrone
Progesterone
D-17β-acetoxy-13β-ethyl-17α-ethinyl-gon-4-en-3-one oxime

The last compound is associated with the levonorgestrel-related oxime chemistry described in the patent. Claim 4 does not eliminate the activity ranges inherited from claim 1.

What does claim 5 cover?

Claim 5 identifies four estrogens:

17α-Ethinylestradiol
Estrone
Estradiol
Estriol

The estrogen must still provide activity corresponding to the 0.02-0.05 mg ethinyl estradiol range and must remain constant through the three treatment phases.

What does claim 6 cover?

Claim 6 narrows the regimen to ethinyl estradiol and norethindrone. This is the most commercially relevant species for the historical Ortho-Novum 7/7/7-type products.

What does claim 7 cover?

Claim 7 combines ethinyl estradiol with the specified oxime progestogen. It is a narrower chemical species claim dependent on the regimen in claim 1.

What does claim 8 cover?

Claim 8 recites the nominal triphasic dose sequence:

Week	Ethinyl estradiol	Progestogen activity
Days 1-7	0.035 mg daily	0.50 mg norethindrone-equivalent
Days 8-14	0.035 mg daily	0.75 mg norethindrone-equivalent
Days 15-21	0.035 mg daily	1.00 mg norethindrone-equivalent
Days 22-28	None	None

Because claim 8 depends on claim 1, it retains the parent claim's contraception, patient, timing, and seven-day hormone-free limitations.

What does claim 9 cover?

Claim 9 is the most commercially specific claim. It requires:

Ethinyl estradiol
Norethindrone
0.035 mg ethinyl estradiol every active day
0.50 mg norethindrone for seven days
0.75 mg norethindrone for seven days
1.0 mg norethindrone for seven days
Seven hormone-free days

Claim 9 most closely tracks the dosage schedule associated with the triphasic norethindrone/ethinyl estradiol product category.

When did U.S. Patent 4,530,839 expire?

Event	Date
Patent issued	July 23, 1985
Statutory term applicable to pre-June 8, 1995 patents	17 years from grant
Expiration	July 23, 2002
Current enforceability	Expired
Patent-term extension or pediatric exclusivity	No current effect identified

The patent was issued before the Uruguay Round Agreements Act changed the U.S. patent term to 20 years from the earliest effective nonprovisional filing date. Its ordinary term therefore ran for 17 years from issuance.[1][2]

The expiration date is determinative for commercial freedom to operate. A manufacturer that practices the claimed regimen today does not face infringement liability under an expired patent.

What is the Orange Book status of U.S. 4,530,839?

U.S. Patent 4,530,839 is not a current enforceable Orange Book barrier to approval or launch of generic norethindrone/ethinyl estradiol products.

The Orange Book lists patents and regulatory exclusivity associated with approved drug products and applications. It does not revive an expired patent. Even if the patent appeared in historical FDA records for a relevant product, its July 2002 expiration eliminates any present patent-based delay to an ANDA applicant.[3]

The patent is a method-of-use patent. It does not protect norethindrone, ethinyl estradiol, or the underlying active ingredients as chemical entities. Its commercial relevance was confined to the claimed contraceptive dosing method.

Were Paragraph IV challenges relevant to this patent?

Paragraph IV litigation is no longer relevant to U.S. Patent 4,530,839 because the patent expired more than two decades ago.

Historically, an ANDA applicant could have challenged the patent by certifying that it was invalid, unenforceable, or would not be infringed. The most relevant potential arguments would have included:

The proposed product did not use the claimed three-phase schedule.
The estrogen dose was not constant.
The progestogen doses did not fall within the claimed norethindrone-equivalent ranges.
The proposed labeling did not instruct the claimed method.
The claims were anticipated or obvious in view of earlier sequential or triphasic contraceptive regimens.
The "progestogenic activity" limitations were indefinite or lacked a reproducible potency standard.
The method claims lacked adequate written-description or enablement support across all listed estrogen and progestogen combinations.

Any such challenge would have been commercially meaningful before July 23, 2002. It has no present launch-blocking effect.

How strong was the patent estate for the triphasic regimen?

The estate was commercially focused but narrow in legal structure.

Strength factor	Assessment
Product specificity	Strong for the exact 0.035/0.50/0.75/1.0 mg regimen
Chemical coverage	Limited; no composition-of-matter protection for the hormones
Method coverage	Stronger where labeling instructed the precise 21/7 schedule
Formulation coverage	Limited; claim 3 covers admixture but does not broadly claim tablet technology
Manufacturing coverage	No meaningful manufacturing-process barrier appears in the asserted claims
Geographic coverage	U.S. only for this patent
Duration	Expired in 2002
Current enforceability	None
Generic-entry risk today	No patent-based risk

The patent's principal commercial value came from aligning a recognizable marketed dosage regimen with a method claim. It did not create a durable franchise around the active ingredients or manufacturing process.

What formulations are protected by U.S. 4,530,839?

The claims can cover combined oral tablets containing a constant 0.035 mg ethinyl estradiol dose and increasing norethindrone doses of 0.5 mg, 0.75 mg, and 1.0 mg over three weeks, followed by seven hormone-free days.

The patent does not expressly require:

A particular tablet excipient
A particular coating
A particular blister-pack design
A particular tablet color
A particular release profile
A particular manufacturing process
A particular brand
A particular pharmaceutical salt or solid-state form

The formulation limitation is functional and regimen-based. A modern generic tablet could have different excipients, compression parameters, coating materials, packaging, or manufacturing equipment and still have practiced the historical method if it delivered the same claimed hormone sequence. Because the patent expired, that distinction has no current infringement consequence.

What patent litigation and settlement risk exists today?

No current patent litigation or settlement agreement involving U.S. Patent 4,530,839 can create an enforceable barrier because the patent expired in 2002.

Historical litigation involving a related branded product, a different patent, or a later formulation should not be attributed to this patent without a direct case citation. The patent number alone does not establish:

A settlement with a generic applicant
A licensed-entry date
A consent judgment
A covenant not to sue
A validity ruling
A finding of infringement

Any historical commercial agreement would be separate from the patent's current legal status.

How does this patent compare with competing contraceptive patent estates?

Patent estate category	Typical protection	Current relevance compared with U.S. 4,530,839
Chemical entity patent	New progestogen or estrogen molecule	Potentially stronger, but not present here
Combination patent	Specific hormone combination	Broader product relevance if unexpired
Formulation patent	Release profile, excipient system, dosage form	Can affect product design after regimen patent expiry
Method-of-use patent	Contraceptive schedule or patient population	This patent category
Manufacturing patent	Crystallization, blending, compression, coating	May affect supply chain freedom to operate
Regulatory exclusivity	New drug, pediatric, orphan, or clinical exclusivity	Separate from patent term
Brand and trade dress	Product name and packaging	Commercial, not patent-based

The main competitive barriers in this product class became generic manufacturing capability, FDA approval requirements, pharmacovigilance, supply reliability, and brand recognition. U.S. 4,530,839 no longer provides exclusivity.

What generic launch scenarios resulted from expiration?

After expiration, a generic applicant could pursue approval for a product using the same triphasic strength sequence without infringing this patent. Relevant regulatory routes included:

ANDA approval for a therapeutically equivalent product
Reference to an approved norethindrone/ethinyl estradiol product
Labeling based on the approved contraceptive indication
Demonstration of pharmaceutical equivalence and bioequivalence where required

A generic product could also alter excipients or packaging while retaining the same active-ingredient schedule. The expired method patent would not require a design-around.

What is the revenue exposure associated with this patent?

Current revenue exposure from this patent is zero in the patent-enforceability sense. No royalty, damages, injunction, or launch-delay exposure remains under an expired U.S. patent.

Historical revenue exposure could have been material for branded triphasic contraceptives because the patent tracked a commercially recognizable dosing schedule. Public patent records alone do not establish brand sales, market share, or the portion of product revenue attributable to this patent. Current commercial value lies in the approved product, manufacturing economics, distribution, and brand position rather than in U.S. 4,530,839.

Key Takeaways

U.S. Patent 4,530,839 protects a 21-day triphasic contraceptive method followed by seven hormone-free days.
The core regimen uses constant estrogen and escalating progestogen doses.
Claim 9 most closely matches the 0.035 mg ethinyl estradiol and 0.50/0.75/1.0 mg norethindrone schedule.
The patent covers a method, not the underlying hormones as chemical entities.
It has limited formulation and manufacturing scope.
The patent issued July 23, 1985, and expired July 23, 2002.
It is not a current Orange Book barrier to generic entry.
Paragraph IV litigation, settlement, and infringement risk under this patent are no longer commercially operative.
Current competition depends on FDA approval, supply, pricing, formulation execution, and brand economics.

FAQs About U.S. Patent 4,530,839

Does U.S. Patent 4,530,839 cover Ortho-Novum 7/7/7?

Its claims closely track the triphasic norethindrone/ethinyl estradiol regimen historically associated with Ortho-Novum 7/7/7-type products. The patent expired in 2002.

Can a generic use the same 0.5 mg, 0.75 mg, and 1.0 mg norethindrone schedule?

Yes. The patent's expiration removed the patent restriction on that schedule, subject to applicable FDA approval and labeling requirements.

Does the patent cover a 28-day continuous hormonal regimen?

No. The claims require seven days without estrogen and progestogen after 21 treatment days.

Does the patent cover progestin-only contraception?

No. The independent claim requires both an estrogen and a progestogen.

Is a foreign patent equivalent to U.S. Patent 4,530,839 still enforceable?

Not necessarily. Patent rights are territorial. The U.S. expiration date does not establish the status of corresponding patents in Europe, Canada, Japan, or other jurisdictions.

References

U.S. Patent No. 4,530,839. (1985). Contraceptive method. United States Patent and Trademark Office. https://patents.google.com/patent/US4530839A/en
United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation. https://www.uspto.gov/patents/laws/patent-term-calculator
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	1226221	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,530,839

Summary for Patent: 4,530,839